Cheyne Capital Management UK LLP boosted its position in shares of iShares NASDAQ Biotechnology Index (NASDAQ:IBB) by 1,152.9% during the fourth quarter, HoldingsChannel reports. The firm owned 21,300 shares of the financial services provider’s stock after buying an additional 19,600 shares during the quarter. iShares NASDAQ Biotechnology Index comprises approximately 1.0% of Cheyne Capital Management UK LLP’s holdings, making the stock its 23rd biggest position. Cheyne Capital Management UK LLP’s holdings in iShares NASDAQ Biotechnology Index were worth $2,274,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. CHURCHILL MANAGEMENT Corp boosted its position in iShares NASDAQ Biotechnology Index by 223.2% during the fourth quarter. CHURCHILL MANAGEMENT Corp now owns 1,801,330 shares of the financial services provider’s stock worth $192,328,000 after purchasing an additional 1,244,066 shares in the last quarter. Clal Insurance Enterprises Holdings Ltd boosted its position in iShares NASDAQ Biotechnology Index by 175.5% during the third quarter. Clal Insurance Enterprises Holdings Ltd now owns 635,875 shares of the financial services provider’s stock worth $212,132,000 after purchasing an additional 405,091 shares in the last quarter. Lockheed Martin Investment Management Co. lifted its position in shares of iShares NASDAQ Biotechnology Index by 200.0% in the fourth quarter. Lockheed Martin Investment Management Co. now owns 329,400 shares of the financial services provider’s stock valued at $35,170,000 after acquiring an additional 219,600 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. lifted its position in shares of iShares NASDAQ Biotechnology Index by 199.9% in the fourth quarter. Harel Insurance Investments & Financial Services Ltd. now owns 313,485 shares of the financial services provider’s stock valued at $33,470,000 after acquiring an additional 208,963 shares in the last quarter. Finally, Commerzbank Aktiengesellschaft FI lifted its position in shares of iShares NASDAQ Biotechnology Index by 159.9% in the fourth quarter. Commerzbank Aktiengesellschaft FI now owns 294,237 shares of the financial services provider’s stock valued at $31,416,000 after acquiring an additional 181,036 shares in the last quarter. Institutional investors own 27.28% of the company’s stock.

Shares of iShares NASDAQ Biotechnology Index (NASDAQ:IBB) opened at $107.54 on Wednesday. iShares NASDAQ Biotechnology Index has a 12-month low of $94.20 and a 12-month high of $119.30.

ILLEGAL ACTIVITY WARNING: This story was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another domain, it was illegally copied and republished in violation of US and international copyright and trademark law. The legal version of this story can be accessed at https://www.thecerbatgem.com/2018/02/14/ishares-nasdaq-biotechnology-index-ibb-shares-bought-by-cheyne-capital-management-uk-llp.html.

About iShares NASDAQ Biotechnology Index

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares NASDAQ Biotechnology Index (NASDAQ:IBB).

Institutional Ownership by Quarter for iShares NASDAQ Biotechnology Index (NASDAQ:IBB)

Receive News & Ratings for iShares NASDAQ Biotechnology Index Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares NASDAQ Biotechnology Index and related companies with MarketBeat.com's FREE daily email newsletter.